Related Experiment Video
Updated: Apr 17, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
2.0K
[Tumour markers in chronic kidney disease]
1Hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
Nephrologie & Therapeutique
|February 25, 2015
Summary
Chronic renal disease can affect tumour marker interpretation. Some markers may be useful for cancer surveillance in these patients, while others show high variability, limiting their clinical utility.
Area of Science:
- Clinical Chemistry
- Nephrology
- Oncology
Background:
- Tumour markers are glycoproteins often used in cancer diagnosis and monitoring.
- Chronic renal disease (CRD) can significantly alter the interpretation of various tumour markers.
- Understanding these alterations is crucial for accurate cancer surveillance in patients with kidney impairment.
Purpose of the Study:
- To evaluate the impact of chronic renal disease on the levels and interpretability of common tumour markers.
- To identify tumour markers that may retain utility for cancer surveillance in patients with CRD.
- To highlight markers with high variability that pose challenges in CRD populations.
Main Methods:
- Review of existing literature on tumour marker behaviour in chronic renal disease.
- Analysis of specific tumour markers including prostate specific antigen, human chorionic gonadotropin, α-fetoprotein, carcinoembryonic antigen, CA 15-3, cytokeratin fragment 21-1, calcitonin, CA125, CA19-9, squamous cell carcinoma antigen, and neurospecific enolase.
- Comparison of marker levels and variability in patients with and without CRD.
Main Results:
- Tumour marker levels, excluding prostate specific antigen, human chorionic gonadotropin, and α-fetoprotein, generally increase with the progression of chronic renal failure.
- For markers like carcinoembryonic antigen, CA 15-3, cytokeratin fragment 21-1, and calcitonin, defined thresholds in CRD populations may permit their use in cancer surveillance.
- Markers such as CA125, CA19-9, squamous cell carcinoma antigen, and neurospecific enolase exhibit high variability in CRD, making their interpretation difficult.
Conclusions:
- Chronic renal disease complicates the interpretation of many tumour markers.
- Certain tumour markers can potentially be used for cancer surveillance in CRD patients if appropriate thresholds are established.
- The high variability of other markers necessitates caution and limits their application in this patient group.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
651
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
651
01:25Chronic Kidney Disease I: Introduction
1.2K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
01:24Chronic Kidney Disease II: Clinical Manifestations
1.1K
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
01:18Chronic Kidney Disease IV: Nursing Management
667
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
667
01:25Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
123
The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
123
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
323
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
323